TORONTO, March 13 /CNW/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding its 510(k) application for PREVU(*) LT for use in the insurance industry. The FDA has additional inquiries to which PreMD is responding. PreMD believes the specific matters raised by the FDA are fully addressable and the Company plans to meet with the FDA at the earliest opportunity to review the planned responses. PreMD submitted the 510(k) application to the FDA in November 2006.
